| p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies E Wattel, C Preudhomme, B Hecquet, M Vanrumbeke, B Quesnel, ... | 776 | 1994 |
| Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-γ and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent … J Liu, A Hamrouni, D Wolowiec, V Coiteux, K Kuliczkowski, D Hetuin, ... Blood, The Journal of the American Society of Hematology 110 (1), 296-304, 2007 | 719 | 2007 |
| Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias R Itzykson, O Kosmider, T Cluzeau, MD Mas, F Dreyfus, O Beyne-Rauzy, ... Leukemia 25 (7), 1147-1152, 2011 | 567 | 2011 |
| A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q P Fenaux, A Giagounidis, D Selleslag, O Beyne-Rauzy, G Mufti, ... Blood, The Journal of the American Society of Hematology 118 (14), 3765-3776, 2011 | 566 | 2011 |
| Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure T Prébet, SD Gore, B Esterni, C Gardin, R Itzykson, S Thepot, F Dreyfus, ... Journal of Clinical Oncology 29 (24), 3322-3327, 2011 | 530 | 2011 |
| Luspatercept in patients with lower-risk myelodysplastic syndromes P Fenaux, U Platzbecker, GJ Mufti, G Garcia-Manero, R Buckstein, ... New England Journal of Medicine 382 (2), 140-151, 2020 | 469 | 2020 |
| Methylation of the p15INK4b Gene in Myelodysplastic Syndromes Is Frequent and Acquired During Disease Progression B Quesnel, G Guillerm, R Vereecque, E Wattel, C Preudhomme, F Bauters, ... Blood, The Journal of the American Society of Hematology 91 (8), 2985-2990, 1998 | 467 | 1998 |
| Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine R Itzykson, S Thépot, B Quesnel, F Dreyfus, O Beyne-Rauzy, P Turlure, ... Blood, The Journal of the American Society of Hematology 117 (2), 403-411, 2011 | 457 | 2011 |
| Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML) N Boissel, H Leroy, B Brethon, N Philippe, S De Botton, A Auvrignon, ... Leukemia 20 (6), 965-970, 2006 | 451 | 2006 |
| Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study C Berthon, E Raffoux, X Thomas, N Vey, C Gomez-Roca, K Yee, ... The Lancet Haematology 3 (4), e186-e195, 2016 | 441 | 2016 |
| TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs) O Kosmider, V Gelsi-Boyer, M Cheok, S Grabar, V Della-Valle, F Picard, ... Blood, The Journal of the American Society of Hematology 114 (15), 3285-3291, 2009 | 359 | 2009 |
| CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d’Etude des Lymphomes de l’Adulte C Bonnet, G Fillet, N Mounier, G Ganem, TJ Molina, C Thiéblemont, ... Journal of clinical oncology 25 (7), 787-792, 2007 | 322 | 2007 |
| Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms O Kosmider, V Gelsi-Boyer, L Slama, F Dreyfus, O Beyne-Rauzy, ... Leukemia 24 (5), 1094-1096, 2010 | 291 | 2010 |
| TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia O Kosmider, V Gelsi-Boyer, M Ciudad, C Racoeur, V Jooste, N Vey, ... Haematologica 94 (12), 1676, 2009 | 281 | 2009 |
| MYD88 L265P mutation in Waldenstrom macroglobulinemia S Poulain, C Roumier, A Decambron, A Renneville, C Herbaux, ... Blood, The Journal of the American Society of Hematology 121 (22), 4504-4511, 2013 | 277 | 2013 |
| Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma C Gisselbrecht, E Lepage, T Molina, B Quesnel, G Fillet, P Lederlin, ... Journal of Clinical Oncology 20 (10), 2472-2479, 2002 | 277 | 2002 |
| Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia D Selimoglu-Buet, O Wagner-Ballon, V Saada, V Bardet, R Itzykson, ... Blood, The Journal of the American Society of Hematology 125 (23), 3618-3626, 2015 | 261 | 2015 |
| Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group N Boissel, O Nibourel, A Renneville, C Gardin, O Reman, N Contentin, ... Journal of Clinical Oncology 28 (23), 3717-3723, 2010 | 261 | 2010 |
| Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents J Merlevede, N Droin, T Qin, K Meldi, K Yoshida, M Morabito, E Chautard, ... Nature communications 7 (1), 10767, 2016 | 227 | 2016 |
| Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des … T Cluzeau, M Sebert, R Rahmé, S Cuzzubbo, J Lehmann-Che, ... Journal of Clinical Oncology 39 (14), 1575-1583, 2021 | 213 | 2021 |
